A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers.

Launched by PFIZER · Mar 5, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to investigate a new medicine called PF-08046032 for adults with advanced cancers, specifically certain types of lymphomas and solid tumors. The study aims to understand how PF-08046032 works on its own and when combined with another medicine called sasanlimab. The trial has three parts: the first part will test PF-08046032 by itself in patients whose cancer has not responded to standard treatments; the second part will evaluate the combination of PF-08046032 and sasanlimab in patients with solid tumors; and the third part will continue to explore this combination based on findings from the first two parts.

To be eligible for the trial, participants must have a confirmed diagnosis of certain advanced cancers that cannot be surgically removed or have spread to other parts of the body. Participants should also be able to provide a sample of their tumor tissue and have a good performance status, meaning they can carry out daily activities without major issues. Throughout the study, participants will receive PF-08046032 through an intravenous (IV) infusion, while those in the second and third parts will also receive sasanlimab through an injection under the skin. It's important to note that this trial is not currently recruiting participants.

Gender

ALL

Eligibility criteria

• INCLUSION CRITERIA:
• 1. Histological or cytological diagnosis of metastatic or unresectable malignancy:
• • Part A1: Participants with lymphomas (cHL, PTCL, large B-cell lymphoma) who have progressed on/after standard therapies
• • Part A2: Participants with solid tumors (NSCLC, HNSCC, melanoma, or other limited tumor types) who have progressed on or following prior immune checkpoint inhibitor if indicated and available
• • Part B: Participants with solid tumors who have either progressed on/after prior immune checkpoint inhibitor, or who have not received prior immune checkpoint inhibitor therapy
• • Part C: Participants with selected tumor type who have not received systemic anticancer treatment for the tumor type (including prior immune checkpoint inhibitor
• • 2. Measurable disease as defined by Lugano Classification for lymphomas or RECIST 1.1 for solid tumors
• • 3. Able to provide tumor tissue(s) as defined by the protocol depending on the Part of the study at enrollment
• • 4. ECOG Performance Status score 0 or 1
• EXCLUSION CRITERIA:
• • 1. Ongoing peripheral neuropathy
• • 2. History of significant immune-mediated adverse event considered related to prior immune-modulatory therapy
• • 3. Known or suspected active autoimmune disease